# Alzheon

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alzheon

- Industry: Biotechnology
- Headquarters: Framingham, US
- Website: www.alzheon.com/
- Total disclosed funding: $196M
- Investors on record: 3

## About

Based in Massachusetts, US, and founded in 2013 by CEP Martin Tolar, Ph.D., Alzheon, Inc. operates as a provider of small-molecule inhibitors for Alzheimer's disease to patients at high genetic risk, including those with the APOE4 gene. In June 2024, Alzheon, Inc. raised USD 100 million in Series E funding led by Alerce Medical Technology Partners.


The company provides a wide range of biopharmaceutical products, such as valiltramiprosate (ALZ-801), a Phase 3 oral anti-amyloid treatment for Alzheimer's disease. Additionally, the firm also provides precision medicine approaches targeting neurodegenerative disorders, focusing on the inhibition of protein misfolding and aggregation.

## Funding rounds

- Round, Oct 14, 2026, $79M
- Series E, Jun 12, 2024, $100M — Alerce Investment Management
- Series A, Apr 8, 2015, $10M — Ally Bridge Group
- Series A, Feb 23, 2015, $4.3M — ARCH Venture Partners, Ally Bridge Group
- Series A, Dec 30, 2014, $3M — ARCH Venture Partners, Ally Bridge Group

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series A
- Alerce Investment Management — Series E